Ronald J Koenig1. 1. Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan 48109-5678, USA. rkoenig@umich.edu
Abstract
PURPOSE OF REVIEW: To provide an update on the pathogenesis and significance of the nonthyroidal illness syndrome. RECENT FINDINGS: The severity of the nonthyroidal illness syndrome predicts mortality, and animal data suggest that, at least in some circumstances, therapy may be beneficial. Multiple abnormalities underlie the syndrome, with induction of type 3 deiodinase and a reduction of type 1 deiodinase potentially contributing to the low T3 state. Induction of type 2 deiodinase in the hypothalamus may underlie the lack of compensatory increase in thyroid-stimulating hormone. Cytokine release from mast cells may be important in establishing a low T4 state secondary to bacterial endotoxin exposure. SUMMARY: It is important to consider the nonthyroidal illness syndrome when interpreting thyroid function in acute and chronic illness. Substantial insight is being made into the underlying mechanisms, but the role, if any, of therapy is still unknown.
PURPOSE OF REVIEW: To provide an update on the pathogenesis and significance of the nonthyroidal illness syndrome. RECENT FINDINGS: The severity of the nonthyroidal illness syndrome predicts mortality, and animal data suggest that, at least in some circumstances, therapy may be beneficial. Multiple abnormalities underlie the syndrome, with induction of type 3 deiodinase and a reduction of type 1 deiodinase potentially contributing to the low T3 state. Induction of type 2 deiodinase in the hypothalamus may underlie the lack of compensatory increase in thyroid-stimulating hormone. Cytokine release from mast cells may be important in establishing a low T4 state secondary to bacterial endotoxin exposure. SUMMARY: It is important to consider the nonthyroidal illness syndrome when interpreting thyroid function in acute and chronic illness. Substantial insight is being made into the underlying mechanisms, but the role, if any, of therapy is still unknown.
Authors: S Pilz; R M A Henry; M B Snijder; R M van Dam; G Nijpels; C D A Stehouwer; O Kamp; A Tomaschitz; T R Pieber; J M Dekker Journal: J Endocrinol Invest Date: 2010-03-05 Impact factor: 4.256
Authors: Jennifer S Janssen; Vibha Sharma; Umarani Pugazhenthi; Celia Sladek; William M Wood; Bryan R Haugen Journal: Mol Cell Endocrinol Date: 2011-03-31 Impact factor: 4.102
Authors: P Iglesias; A Muñoz; F Prado; M T Guerrero; M C Macías; E Ridruejo; P Tajada; C García-Arévalo; J J Díez Journal: J Endocrinol Invest Date: 2010-02-24 Impact factor: 4.256
Authors: Alexandra M Dumitrescu; Caterina Di Cosmo; Xiao-Hui Liao; Roy E Weiss; Samuel Refetoff Journal: Antioxid Redox Signal Date: 2010-04-01 Impact factor: 8.401
Authors: Ulla T Schultheiss; Inga Steinbrenner; Matthias Nauck; Markus P Schneider; Fruzsina Kotsis; Seema Baid-Agrawal; Elke Schaeffner; Kai-Uwe Eckardt; Anna Köttgen; Peggy Sekula Journal: Clin Kidney J Date: 2020-06-04